Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01871350 · ClinicalTrials.gov registry record · NA

Nutrition Intervention During Chemotherapy

A NA study of Cancer Patients Receiving Chemotherapy or Chemoradiotherapy, sponsored by Texas A&M University.

Completed
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT01871350: Completed NA study of Cancer Patients Receiving Chemotherapy or Chemoradiotherapy, sponsored by Texas A&M University.

NCT01871350 is a NA study of Cancer Patients Receiving Chemotherapy or Chemoradiotherapy that has completed, run by Texas A&M University. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01871350, a NA study of Cancer Patients Receiving Chemotherapy or Chemoradiotherapy, has completed, sponsored by Texas A&M University.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

Weight loss and muscle wasting commonly occurs in patients with cancer, negatively influencing their quality of life, treatment response and survival. Weight loss has been reported as a side effect of chemotherapy treatment in cancer. Weight changes may be the consequence of energy imbalance and disturbances in protein metabolism (through different factors linked with chemotherapy), such as reduced caloric and protein intake (partly related to depression), poor treatment tolerance, hormonal alterations, systemic inflammation etc. This results in body composition modifications in favor of fat gain and/or lean body mass loss in early stage cancer and loss of both fat mass and lean mass in advanced cancer. Depletion of lean tissue in cancer patients is related to short survival, and decreased skeletal muscle mass and function may result in fatigue and inactivity, which contributes to fat mass changes and can be responsible for chemo-toxicity and increased mortality. Gains in muscle mass are difficult to achieve in cancer unless specific metabolic abnormalities are targeted. Recently, the investigators observed that essential amino acid mixtures (EAA) are able to induce protein anabolism in patients with stage III and IV non-small cell lung cancer. Previous experimental research and clinical studies in cachectic conditions (including cancer) indicate that polyunsaturated fatty acids (PUFA) are able to attenuate protein degradation by improving the anabolic response to feeding and by decreasing the acute phase response. Eicosapentaenoic acid (EPA) (in combination with docosahexaenoic acid (DHA)) has been shown to effectively inhibit weight loss in several disease states; however, weight and muscle mass gain was not present or minimal. Recent studies examining the effect of fish oil supplementation in relation to chemotherapy have been inconclusive but found potential beneficial effects on physical performance and increased efficacy of first-line chemotherapy in patients

Primary Outcome

The acute change in whole-body protein synthesis rate before and after intake of meal is determined on the first test day for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 10 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

Interventions

  • DIETARY_SUPPLEMENT Daily intake for 10 weeks (+/- 2 weeks)

Study Locations (1)

Texas

  • Texas A&M University - College Station

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2013-04-26
Est. Completion 2015-11-03
Phase NA
Texas A&M University

95 total trials

What the finished NCT01871350 record still lists

NCT01871350 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Cancer Patients Receiving Chemotherapy or Chemoradiotherapy appearing as the primary indexed condition, and to 1 intervention - of which Daily intake for 10 weeks (+/- 2 weeks) is the first listed.

NCT01871350 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT01871350 about?

NCT01871350 is a clinical study titled "Nutrition Intervention During Chemotherapy". Weight loss and muscle wasting commonly occurs in patients with cancer, negatively influencing their quality of life, treatment response and survival. Weight loss has been reported as a side effect of chemotherapy treatment in cancer. Weight changes may be the consequence of energy imbalance and dis...

What is the current status of trial NCT01871350?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2013-04-26. Estimated completion is 2015-11-03.

What conditions does trial NCT01871350 study?

This clinical trial studies the following conditions: Cancer Patients Receiving Chemotherapy or Chemoradiotherapy.

What interventions are being tested in trial NCT01871350?

The interventions under investigation include: Daily intake for 10 weeks (+/- 2 weeks) (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01871350?

This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01871350 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT01871350's enrollment target sits among peer trials

31 1592nd of 2000 higher than 408 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01871350, the US trial registry maintained by the National Library of Medicine. NCT01871350 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.